BIOF
Blue Biofuels, Inc.0.1730
-0.0050-2.81%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
54.62MP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
10-Q
10-Q
Q2 FY2025 results
Blue Biofuels posted a Q2 net loss of $920,752, up 68% y/y from $548,823, driven by higher R&D and G&A expenses tied to equity-based compensation, while YTD net loss narrowed 22% y/y to $1,164,585 thanks to $444,970 in DOE grant income offsetting costs. Operating expenses climbed to $902,604 q/q from $688,804 (derived), with no revenue yet as the CTS pilot plant advances toward commercialization. Cash dwindled to $8,026 from $48,797 at year-end, after $298,723 used in operations; financing brought in $451,250 via notes and stock sales, but total liabilities hit $4,620,330 including $1,515,000 milestone-tied related-party debt. The joint venture with Vertimass eyes a 5-10 million gallon SAF facility in Florida. No non-GAAP metrics disclosed in the 10-Q. Regulatory hurdles could delay biofuel plant permits.
10-Q
Q1 FY2025 results
Blue Biofuels narrowed its Q1 operating loss to $688,805 from $903,617 a year earlier, thanks to a $444,970 government grant offsetting expenses, while R&D costs dropped 41.2% y/y to $350,707 on lower stock-based compensation. Net loss improved to $243,833, or $0.001 per diluted share, from $946,872, or $0.003, with EPS aligning to 308.5 million weighted shares. Cash dipped to $7,583 after $154,630 in equipment buys, but operations turned positive at $13,416 and financing added $100,000 from related-party notes; total debt holds at $1.75 million, mostly milestone-tied. The $1.15 million DOE SBIR grant fuels CTS tech scaling for cellulosic biofuels. No revenue yet. Regulatory hurdles loom in EPA approvals for commercial plants.
10-K
FY2024 results
Blue Biofuels narrowed its FY2024 net loss to $1.4 million from $3.1 million in 2023, buoyed by a $2.4 million gain on debt extinguishment while ramping up R&D spend to $2.3 million amid pilot plant optimizations. No revenue yet, but Q4 saw $285,000 in DOE grant income—up from $234,000 for all of 2023—fueling CTS tech advancements toward commercialization. Stock-based comp surged, inflating G&A to $1.7 million, yet cash ticked up to $49,000 on $1.1 million in financing, including $930,000 in notes. The VertiBlue JV eyes 10 million gallons of SAF production post-financing. Debt overhang lingers at $4.2 million, mostly related-party. Regulatory delays could stall quarterly progress.
10-Q
Q3 FY2024 results
Blue Biofuels swung to a $1.9 million net income for Q3 ended September 30, 2024, from a $332,000 loss a year earlier, thanks to a $2.4 million gain on extinguishing legacy bankruptcy debt while operating expenses climbed 26% year-over-year to $648,000, driven by higher research and development outlays. Year-to-date through nine months, the company narrowed its net loss to $370,000 from $2.6 million, with operating cash use dropping 47% to $791,000 amid reduced stock-based compensation. Cash rose to $149,000, bolstered by $930,000 in new convertible notes from related parties, though total liabilities stand at $4.0 million, mostly milestone-tied and non-cash payable. A fresh $1.15 million DOE grant fuels CTS commercialization. Yet regulatory hurdles for biofuels production loom large.
IPO
Website
Employees
Sector
Industry